ClinicalTrials.gg
TerminatedNCT03363776Updated Dec 19, 2020Results posted

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

A Phase 1/2 interventional study of BMS-986277 and Nivolumab in Cancer, sponsored by Bristol-Myers Squibb. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate experimental medication BMS-986277 given alone and in combination with Nivolumab in patients with epithelial cancers.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 10 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Histological or cytological confirmation of and/or unresectable metastatic colorectal, prostate, pancreatic, breast, ovarian, or urothelial carcinoma with measureable disease for solid tumors per v1.1 and for prostate carcinoma per PCWG3
  • Presence of at least 2 lesions: at least one with as defined by RECIST v1.1 for solid tumors and by PCWG3 for prostate carcinoma for response assessment; at least 1 lesion must be accessible for in addition to the target lesion
  • Participants must have received, and then progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting, if such a therapy exists, and have been considered for all other potentially efficacious therapies prior to enrollment
  • performance status less than or equal to 2

Exclusion criteria

Exclusion Criteria:

  • Participants with active central nervous system (CNS) , untreated , or with the CNS as the only site of disease
  • Participants with carcinomatous meningitis
  • Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study treatment
  • Participants with active, known, or suspected disease

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Monotherapy

    BMS-986277 administered alone

    Biological: BMS-986277

  • Experimental
    Combination Dose Escalation Therapy

    BMS-986277 administered in combination with Nivolumab

    Biological: BMS-986277 · Biological: Nivolumab

  • Experimental
    Combination Expansion Therapy

    BMS-986277 monotherapy with option for subsequent Nivolumab therapy

    Biological: BMS-986277 · Biological: Nivolumab

Interventions

  • BiologicalBMS-986277

    Specified dose on specified days

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-963558

06

What researchers measure

Primary outcomes

  1. Number of Participants With an Adverse Event (AE)

    Number of participants who experienced an AE during the course of the study.

    Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)

  2. Number of Participants With a Serious Adverse Event (SAE)

    Number of participants who experienced a SAE during the course of the study.

    Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)

  3. Number of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) Criteria

    Number of participants who experienced an AE meeting protocol-defined DLT criteria during the course of the study.

    Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)

  4. Number of Participants With an Adverse Event (AE) Leading to Discontinuation

    Number of participants who experienced an AE leading to discontinuation during the course of the study.

    Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)

  5. Number of Participants With an Adverse Event (AE) Leading to Death

    Number of participants who experienced an AE leading to death during the course of the study.

    Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)

  6. Number of Participants With a Clinical Laboratory Test Abnormality

    Number of participants who experienced a clinical laboratory test abnormality during the course of the study.

    Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)

  7. Number of Participants With a Vital Sign Abnormality or Other Safety Biomarkers

    Number of participants who experienced a vital sign abnormality or other safety biomarkers during the course of the study.

    Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of all treated participants whose BOR is either CR or PR. BOR was determined by investigators for the reported data. Estimate of ORR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method

    Time frame: at Weeks 8, 16 and 24

  2. Disease Control Rate (DCR)

    DCR includes complete response (CR), partial response (PR), and stable disease (SD). Estimate of DCR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method

    Time frame: at Weeks 8, 16 and 24

  3. Median Duration of Response (mDOR)

    DOR for a participant with a BOR of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1/PCWG3 or death, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation)

    Time frame: at Weeks 8, 16 and 24

  4. Median Progression-Free Survival (mPFS)

    PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.

    Time frame: at Weeks 8, 16 and 24, to progression

  5. Progression-Free Survival Rate (PFSR)

    PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.

    Time frame: at Weeks 8, 16 and 24

  6. Cmax

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Cmax is defined as the maximum observed blood concentration.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  7. Tmax

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Tmax is defined as the time of maximum observed blood concentration.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  8. AUC(0-T)

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to time of last quantifiable concentration.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  9. AUC(INF)

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(INF) is the area under the blood concentration-time curve from time zero extrapolated to infinite time.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  10. T-HALF

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. T-HALF is defined as the apparent terminal half-life.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  11. CLT

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. CLT is defined as the total body clearance.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  12. Vss

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Vss is defined as the volume of distribution at steady-state.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  13. Vz

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Vz is defined as the volume of distribution of the elimination phase.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  14. AUC(0-48)

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to 48 hours postdose

    Time frame: Cycle 1 (from time zero to 48 hours postdose)

  15. AUC(0-8)

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to 8 hours postdose

    Time frame: Cycle 1 (from time zero to 8 hours postdose)

  16. C48

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. C48 is defined as the blood concentration at 48 hours postdose.

    Time frame: Cycle 1 at 48 hours postdose

  17. Css-avg

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Css-avg is defined as the average blood concentration over a dosing interval at steady state (AUC\[0-48\]/48).

    Time frame: Cycle 1 (from time zero to 48 hours postdose)

  18. AI_AUC

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC accumulation index; ratio of AUC(0-48) on Cycle 1 Day 19 to AUC(0-48) on Cycle 1 Day 15 for monotherapy.

    Time frame: Cycle 1 (Day 19, Day 15)

  19. AI_Cmax

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Cmax accumulation index; ratio of Cmax on Cycle 1 Day 19 to Cmax on Cycle 1 Day 15 for monotherapy.

    Time frame: Cycle 1 (Day 19, Day 15)

  20. T-HALFeff

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. T-HALFeff is defined as effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC, Cmax)

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  21. Ctrough

    Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Ctrough is defined as the trough observed blood concentration.

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

  22. Number of Participants With a Positive Antibody-Drug-Antibody (ADA) Response

    Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment. Frequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment

    Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits

07

Results

Posted Dec 19, 2020

Participant flow

Participant flow — Overall Study
MilestoneArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Started433
Completed101
Not completed332
Withdrew: Progressive disease231
Withdrew: Study drug toxicity001
Withdrew: Death100

Outcome measures

PrimaryNumber of Participants With an Adverse Event (AE)

Number of participants who experienced an AE during the course of the study.

Time frame:
from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Reported as:
Number · Number of Participants
Number of Participants With an Adverse Event (AE)
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Number of Participants With an Adverse Event (AE)NANANA
PrimaryNumber of Participants With a Serious Adverse Event (SAE)

Number of participants who experienced a SAE during the course of the study.

Time frame:
from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Reported as:
Number · Number of Participants
Number of Participants With a Serious Adverse Event (SAE)
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Number of Participants With a Serious Adverse Event (SAE)NANANA
PrimaryNumber of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) Criteria

Number of participants who experienced an AE meeting protocol-defined DLT criteria during the course of the study.

Time frame:
from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Reported as:
Number · Number of Participants
Number of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) Criteria
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Number of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) CriteriaNANANA
PrimaryNumber of Participants With an Adverse Event (AE) Leading to Discontinuation

Number of participants who experienced an AE leading to discontinuation during the course of the study.

Time frame:
from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Reported as:
Number · Number of Participants
Number of Participants With an Adverse Event (AE) Leading to Discontinuation
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Number of Participants With an Adverse Event (AE) Leading to DiscontinuationNANANA
PrimaryNumber of Participants With an Adverse Event (AE) Leading to Death

Number of participants who experienced an AE leading to death during the course of the study.

Time frame:
from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Reported as:
Number · Number of Participants
Number of Participants With an Adverse Event (AE) Leading to Death
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Number of Participants With an Adverse Event (AE) Leading to DeathNANANA
PrimaryNumber of Participants With a Clinical Laboratory Test Abnormality

Number of participants who experienced a clinical laboratory test abnormality during the course of the study.

Time frame:
from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Reported as:
Number · Number of Participants
Number of Participants With a Clinical Laboratory Test Abnormality
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Number of Participants With a Clinical Laboratory Test AbnormalityNANANA
PrimaryNumber of Participants With a Vital Sign Abnormality or Other Safety Biomarkers

Number of participants who experienced a vital sign abnormality or other safety biomarkers during the course of the study.

Time frame:
from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Reported as:
Number · Number of Participants
Number of Participants With a Vital Sign Abnormality or Other Safety Biomarkers
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Number of Participants With a Vital Sign Abnormality or Other Safety BiomarkersNANANA
SecondaryObjective Response Rate (ORR)

ORR is defined as the proportion of all treated participants whose BOR is either CR or PR. BOR was determined by investigators for the reported data. Estimate of ORR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method

Time frame:
at Weeks 8, 16 and 24
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Objective Response Rate (ORR)NANANA
SecondaryDisease Control Rate (DCR)

DCR includes complete response (CR), partial response (PR), and stable disease (SD). Estimate of DCR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method

Time frame:
at Weeks 8, 16 and 24
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Disease Control Rate (DCR)NANANA
SecondaryMedian Duration of Response (mDOR)

DOR for a participant with a BOR of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1/PCWG3 or death, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation)

Time frame:
at Weeks 8, 16 and 24
Reported as:
Number · Number of Participants
Median Duration of Response (mDOR)
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Median Duration of Response (mDOR)NANANA
SecondaryMedian Progression-Free Survival (mPFS)

PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.

Time frame:
at Weeks 8, 16 and 24, to progression
Reported as:
Number · Number of Participants
Median Progression-Free Survival (mPFS)
Number of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Median Progression-Free Survival (mPFS)NANANA
SecondaryProgression-Free Survival Rate (PFSR)

PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.

Time frame:
at Weeks 8, 16 and 24
Reported as:
Number · Percentage of Participants
Progression-Free Survival Rate (PFSR)
Percentage of ParticipantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Progression-Free Survival Rate (PFSR)NANANA
SecondaryCmax

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Cmax is defined as the maximum observed blood concentration.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Geometric mean · µg/mL
Cmax
µg/mLArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
CmaxNA ± NANA ± NANA ± NA
SecondaryTmax

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Tmax is defined as the time of maximum observed blood concentration.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Median · hour
Tmax
hourArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
TmaxNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryAUC(0-T)

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to time of last quantifiable concentration.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Geometric mean · µg.h/mL
AUC(0-T)
µg.h/mLArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
AUC(0-T)NA ± NANA ± NANA ± NA
SecondaryAUC(INF)

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(INF) is the area under the blood concentration-time curve from time zero extrapolated to infinite time.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Geometric mean · µg.h/mL
AUC(INF)
µg.h/mLArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
AUC(INF)NA ± NANA ± NANA ± NA
SecondaryT-HALF

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. T-HALF is defined as the apparent terminal half-life.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Mean · hour
T-HALF
hourArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
T-HALFNA ± NANA ± NANA ± NA
SecondaryCLT

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. CLT is defined as the total body clearance.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Geometric mean · liter
CLT
literArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
CLTNA ± NANA ± NANA ± NA
SecondaryVss

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Vss is defined as the volume of distribution at steady-state.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Geometric mean · liter
Vss
literArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
VssNA ± NANA ± NANA ± NA
SecondaryVz

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Vz is defined as the volume of distribution of the elimination phase.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Geometric mean · liter
Vz
literArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
VzNA ± NANA ± NANA ± NA
SecondaryAUC(0-48)

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to 48 hours postdose

Time frame:
Cycle 1 (from time zero to 48 hours postdose)
Reported as:
Geometric mean · µg.h/mL
AUC(0-48)
µg.h/mLArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
AUC(0-48)NA ± NANA ± NANA ± NA
SecondaryAUC(0-8)

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to 8 hours postdose

Time frame:
Cycle 1 (from time zero to 8 hours postdose)
Reported as:
Geometric mean · µg.h/mL
AUC(0-8)
µg.h/mLArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
AUC(0-8)NA ± NANA ± NANA ± NA
SecondaryC48

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. C48 is defined as the blood concentration at 48 hours postdose.

Time frame:
Cycle 1 at 48 hours postdose
Reported as:
Geometric mean · µg/mL
C48
µg/mLArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
C48NA ± NANA ± NANA ± NA
SecondaryCss-avg

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Css-avg is defined as the average blood concentration over a dosing interval at steady state (AUC\[0-48\]/48).

Time frame:
Cycle 1 (from time zero to 48 hours postdose)
Reported as:
Geometric mean · µg/mL
Css-avg
µg/mLArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Css-avgNA ± NANA ± NANA ± NA
SecondaryAI_AUC

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC accumulation index; ratio of AUC(0-48) on Cycle 1 Day 19 to AUC(0-48) on Cycle 1 Day 15 for monotherapy.

Time frame:
Cycle 1 (Day 19, Day 15)
Reported as:
Geometric mean · ratio AUC(0-48),C1D19 to AUC(0-48),C1D15
AI_AUC
ratio AUC(0-48),C1D19 to AUC(0-48),C1D15Arm A (Part 1)Arm B (Part 1)Arm C (Part 1)
AI_AUCNA ± NANA ± NANA ± NA
SecondaryAI_Cmax

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Cmax accumulation index; ratio of Cmax on Cycle 1 Day 19 to Cmax on Cycle 1 Day 15 for monotherapy.

Time frame:
Cycle 1 (Day 19, Day 15)
Reported as:
Geometric mean · ratio of Cmax,C1D19 to Cmax,C1D15
AI_Cmax
ratio of Cmax,C1D19 to Cmax,C1D15Arm A (Part 1)Arm B (Part 1)Arm C (Part 1)
AI_CmaxNA ± NANA ± NANA ± NA
SecondaryT-HALFeff

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. T-HALFeff is defined as effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC, Cmax)

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Median · hour
T-HALFeff
hourArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
T-HALFeffNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryCtrough

Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Ctrough is defined as the trough observed blood concentration.

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Geometric mean · µg/mL
Ctrough
µg/mLArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
CtroughNA ± NANA ± NANA ± NA
SecondaryNumber of Participants With a Positive Antibody-Drug-Antibody (ADA) Response

Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment. Frequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment

Time frame:
Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Reported as:
Number · Number of participants
Number of Participants With a Positive Antibody-Drug-Antibody (ADA) Response
Number of participantsArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Number of Participants With a Positive Antibody-Drug-Antibody (ADA) ResponseNANANA

Adverse events

Collected over AEs/SAEs are collected from the first dose date until the last dose date + 100 days, assessed up to February 2020 (approx. 26 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Part 1)2/4 (50%)1/4 (25%)4/4 (100%)
Arm B (Part 1)2/3 (66.7%)0/3 (0%)3/3 (100%)
Arm C (Part 1)2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/40/32/3
Cytokine release syndromeImmune system disorders0/40/31/3
DehydrationMetabolism and nutrition disorders0/40/31/3
AscitesGastrointestinal disorders1/40/30/3
Most frequent other events
Showing 10 of 44
Most frequent other events
EventArm A (Part 1)Arm B (Part 1)Arm C (Part 1)
FatigueGeneral disorders2/41/33/3
PyrexiaGeneral disorders0/40/33/3
NauseaGastrointestinal disorders3/41/32/3
VomitingGastrointestinal disorders1/41/32/3
ChillsGeneral disorders1/41/32/3
Influenza like illnessGeneral disorders0/42/30/3
Back painMusculoskeletal and connective tissue disorders0/41/32/3
HeadacheNervous system disorders1/42/31/3
DiarrhoeaGastrointestinal disorders2/40/30/3
Decreased appetiteMetabolism and nutrition disorders2/41/30/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A (Part 1)Arm B (Part 1)Arm C (Part 1)Total
Mean61 ± 2.459 ± 10.447 ± 12.157 ± 9.9
Age, Customized
Age, Customized(Participants)Arm A (Part 1)Arm B (Part 1)Arm C (Part 1)Total
> 65 years0101
<= 65 years4239
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Part 1)Arm B (Part 1)Arm C (Part 1)Total
Female2125
Male2215
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A (Part 1)Arm B (Part 1)Arm C (Part 1)Total
Hispanic or Latino0000
Not Hispanic or Latino1012
Unknown or Not Reported3328
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Part 1)Arm B (Part 1)Arm C (Part 1)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White43310
More than one race0000
Unknown or Not Reported0000
08

Study locations

3 sites
  • Sanford Research
    Sioux Falls, South Dakota 57104, United States
  • Local Institution
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 1Z5, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Nov 2019, 23 months.

Results were first posted in Dec 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2017
First posted
Dec 6, 2017
StartActual
Dec 6, 2017
Primary completionActual
Nov 22, 2019
CompletionActual
Nov 22, 2019
Results first posted
Dec 19, 2020
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03363776
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Dec 6, 2017
Primary completion
Nov 22, 2019
Completion
Nov 22, 2019
Results posted
Dec 19, 2020
Last update
Dec 19, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion